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BACKGROUND: Nifurtimox (NF) is one of the only two drugs currently available 28 
for Chagas disease (ChD) treatment. However, there is scarce data on NF safety, 29 
and many physicians defer or refuse NF treatment because of concerns about drug 30 
tolerance. 31 
METHODS: Retrospective study of adverse drug reactions (ADRs) associated with 32 
NF treatment of ChD. Children received NF doses of 10-15 mg/kg/day for 60-90 33 
days, and adults 8-10 mg/kg/day for 30 days.  34 
RESULTS: 215 children (median age: 2.6yrs, range 0-17) and 105 adults (median 35 
age: 34yrs, range 18-57) were enrolled. Overall, 127/320 (39.7%) patients 36 
developed ADRs, with an incidence of 64/105 in adults, and 63/215 in children (OR 37 
= 3.7, 95%CI [2.2;6.3]). We observed 215 ADRs, 131 in adults (median: 2 38 
events/patient (IQR25-75= 1-3) and 84 in children (median: 1 event/patient (IQR25-75= 39 
1-1.5) (PAdjusted < 0.001). ADRs were mainly mild and moderate. Severe ADRs 40 
were infrequent (1.2% in children and 0.9% in adults). Nutritional, central nervous 41 
and digestive systems were the most frequently affected, without differences 42 
between both groups. 43 
Treatment was discontinued in 31/320 (9.7%) patients without differences between 44 
groups. However, ADR-related discontinuations occurred more frequently in adults 45 
than in children (OR = 5.5, 95%CI = [1.5;24]).  46 
CONCLUSIONS: Our study supports the safety of NF for ChD treatment. Delaying 47 
NF treatment due to safety concerns does not seem to be supported by the 48 
evidence. 49 
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Background     51 
Chagas disease (ChD) is a silent but devastating disease caused by infection with 52 
the parasite Trypanosoma cruzi. The disease is endemic to the Americas, from the 53 
USA to Argentina, with over 7 million people currently infected in Latin America. 54 
ChD has expanded to many countries of the world via immigration, most  cases 55 
reported in Europe, North America, Australia and Japan(1). 56 
Most patients are asymptomatic during acute ChD. The acute phase is followed by 57 
a chronic asymptomatic stage that will eventually lead to irreversible heart disease 58 
in up to 30% of the infected patients many years later(2). Over 7,000 deaths occur 59 
yearly due to complications of Chagas.  60 
The current treatment for ChD is limited to two nitro-heterocyclic drugs, nifurtimox 61 
(NF) and benznidazole (BZ), both with similar effectiveness. Despite both drugs 62 
having been available since the early 70s, treatment recommendations vary 63 
significantly from country to country and the evidence-base for the current 64 
treatment regimens is limited. This failure to treat may possibly be explained by 65 
many obstacles, including health care providers’ low awareness of the diseases 66 
and its treatment options, overblown concerns about side effects, low access to 67 
healthcare for many patients, lack of an optimal straightforward test of treatment 68 
response, widespread drug shortages and irregular supplies, and regulatory 69 
barriers . 70 
The most commonly observed NF´ADRs are anorexia and weight loss, irritability, 71 
sleepiness, and other nervous system signs and symptoms (4, 5). NF is also 72 
associated with rash, pruritus, and drug-associated hepatitis but less frequently 73 
than BZN. Depression, peripheral neuropathy, and psychiatric symptoms have also 74 
been reported. Similar to BZN, NF-associated ADRs seem much more common 75 
and severe in adults (6)and are usually mild in children, including neonates (7, 8)  . 76 
However, current tolerability data comes mainly from small cohort studies. The 77 
pharmacological basis for the differences in the incidence of adverse events 78 
remain to be studied (9).  79 
Here, we present results from a large cohort of ChD patients including infants, 80 
children and adults treated with NF, describing and comparing safety among adults 81 
and pediatric patients.  82 
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Results  83 
Population characteristics  84 
Medical records of ChD patients treated at our Institution were reviewed, and 372 85 
patients who were prescribed NF were identified. However, 52 patients were 86 
excluded because they did not start treatment (i.e. did not fill in NF prescription). 87 
The remaining 320 patients were included in the study. A total of 215 pediatric 88 
patients [0-17yrs) and 105 adults were included. Among children were: n=56 (0 - 89 
7mos) n=43 (8mos - 1yr), n=44 (2 - 6yrs), n=37 (7 - 11yrs) and n=35 (12-17yrs).  A 90 
low rate of loss to follow-up was observed, as only 16/320 (5%) patients 91 
abandoned the study (see flowchart diagram in Figure 1).  92 
In general, male and female subjects were well balanced in children but not in 93 
adults where 87.6% of subjects were female (most of them were mothers of 94 
children assisted in our service). The route of infection was: congenital in 131, 95 
undetermined in 154, vectorial in 32 and by blood transfusion in 3 cases (Table 1). 96 
Overall, most patients were asymptomatic 289/320 (90.3%) and only 31/320 97 
(9.7%) were symptomatic. Considering the route of infection, patients infected by 98 
the vector route were predominantly symptomatic 12/32 (37.5%) and the most 99 
frequent symptom was the ocular chagoma in 11/12 cases. In patients infected by 100 
the remaining routes (congenital, undetermined and blood transfusion), 101 
symptomatic cases were infrequent 19/288 (6.6%). Symptomatic cases were 102 
observed mainly in infants under 2 years 16/19 (84.2%), and the most affected 103 
organ was the liver (12/19 cases).    104 
A clinical improvement was observed in all but one symptomatic patient during 105 
treatment. Only one 3-month-old infant, coinfected with T.cruzi and HIV by the 106 
transplacental route, did not show clinical improvement. , The patient developed  107 
encephalitis and myocarditis related to HIV infection, and died during NF treatment 108 
due to respiratory complications.  109 
ADRs incidence and relationship  110 
Overall, 127/320 patients (39.7%) developed ADRs, with an incidence in adults of 111 
64/105 (60.9%), and of 63/215 (29.3%) in children (OR = 3.7, CI95% = [2.2 - 6.3]; 112 
PAdjusted <0.001). 113 
A total of 215 ADRs in 127 patients were observed. In 64 adults, 131 ADRs were 114 
observed with a median of 2 events per patient (IQR25-75 = 1-3) and in 63 children, 115 
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84 ADRs were observed with a median of 1 event per patient (IQR25-75 = 1- 1.5); 116 
(PAdjusted <0.001).  117 
NF-related ADRs were more frequent in adults (79.7%) than in children (7.9%) 118 
(OR=9.9, CI95% = [3.7 - 33]; PAdjusted <0.001; see Table 2 for further details). No 119 
significant differences were observed in the amount of ADRs comparing patients 120 
during the acute (vectorial and infants younger than 8 months of age) and the 121 
chronic phase of infection (P_Adjusted = 0.4). 122 
The number of ADRs was associated with incomplete treatment: 2.58 123 
events/patient in subjects that discontinued treatment vs 1.55 events/patient in 124 
those with completed treatment (PAdjusted <0.001). Moreover, differences remained 125 
when considering both cohorts separately (adults: PAdjusted = 0.028; children: 126 
PAdjusted = 0.016).    127 
The profile of the 215 ADRs is shown in Table 3. The systems most commonly 128 
affected were nutritional 75/215 (34.9%), Central Nervous System (CNS) 61/215 129 
(28,4%) and digestive 38/215 (17.7%) without differences between adults and 130 
children. Few adverse skin effects (20/215, 9.3%) were observed in both groups 131 
and hematological ADRs (7/215 events) were observed only in children (OR = Inf, 132 
CI95% = [2.3 - Inf]; PAdjusted=0.005). 133 
Time of onset of ADRs was recorded for 130/215 ADRs in 64/127 patients (50.4%). 134 
Overall, 93.8% of ADRs appeared within 30 days of treatment. ADRs median onset 135 
time (IQR25-75) was:  5 (2.5 - 10.2) days for digestive, 5.5 (1.5 - 11) days for CNS, 8 136 
(0.75 - 26) days for nutritional, and 13 (10 - 20) days for skin.  137 
ADRs had an earlier onset in adults, who presented a median onset time of 6.5 138 
days (IQR25-75 = 1.5 - 9), compared to children, who presented a median onset time 139 
of 12 days (IQR25-75 = 9.7 - 21; PAdjusted <0.001).  140 
Severity  141 
ADRs severity is described in Table 2. Most ADRs were mild (74.9%) and 142 
moderate (16.3%) and resolved without sequelae. Severe ADRs were infrequent: 143 
2/215 (0.9%).  Severe ADRs occurred in 1 adult and in 1 child (see Table 2). The 144 
adult was a woman in her 30´s, who developed a headache with a defined 145 
relationship to NF.  ADR resolved without consequences, but NF treatment was 146 
discontinued. The child was in the 8mos-2yrs age range, who presented severe 147 
leukopenia, but also resolved without consequences and he was able to complete 148 
treatment.  149 
The severity of ADRs was associated with treatment discontinuation in adults, with 150 
67% of discontinuations in the 15 subjects that presented moderate/severe ADRs 151 
compared to 6.1% in the 49 subjects that presented mild ADRs (OR = 27.8, CI95% 152 
=  [5.1 - 212]; PAdjusted  <0.001). In children no association was observed (OR = 2.4, 153 
CI95% = [0.04 - 35]; PAdjusted = 0.4). 154 
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Serious events were observed in 2 patients. One patient showed a serious event 155 
unrelated to NF. The patient died due to complications related to HIV infection and 156 
it was described previously. The other patient, a female in her 30´s (not the one 157 
mentioned in the previous paragraph), presented tremors, dysarthria and panic 158 
attacks which required hospitalization. This patient made a full recovery, but 159 
treatment was discontinued.  160 
Treatment completion  161 
Overall treatment was completed in 289/320 patients (90.3%) without differences 162 
between children (92.6%) and adults (85.7%; Table 4). Treatment discontinuation 163 
took place in 31/320 (9.7%) patients, but only 14/320 (4.4%) were related to ADRs 164 
(Table 5). ADRs-related discontinuations occurred more frequently in adults (9.5%) 165 
than in children (1.9%; OR = 5.5, CI95% = [1.5 - 24]; PAdjusted = 0.008). Notably, the 166 
main cause of treatment discontinuation in children was related to moderate skin 167 
ADRs (3/4 children, see tables 4 and 5).  168 
A total of 20/320 (6.2%)  subjects temporarily interrupted NF (see table 4), without 169 
differences among adults (9.5%) and children (4.7%, OR = 2.1, CI95% =  [0.77 - 170 
5.9];  PAdjusted = 0.14). Temporary interruption causes were in 7 adults and 5 171 
children due to ADRs and the remaining 8 patients by personal decision. The 172 
median temporary interruption length was 7 days (IQR25-75: 2- 9 days) with no 173 
differences between adults and children.  174 
ADRs leading to temporary treatment interruptions were digestive (5), CNS (3), 175 
skin (2), cardiovascular (2), and nutritional (2) among adults, and digestive (2), skin 176 
(2) and hematologic (2) among children. Treatment discontinuation occurred in 4 of 177 
these 12 patients (2 adults, 2 children). The remaining patients completely 178 
recovered after symptomatic treatment and/or transient interruption of NF.  179 
For those 289 patients who completed treatment, mean dose, number of tablets 180 
and the length of treatment are described in Table 6.  181 
Pediatric cohort analysis 182 
A sub-analysis by age group of the pediatric cohort was carried out to elucidate 183 
whether there was any trend in the number, frequency or type of ADRs.  184 
A high rate of treatment completion (92.6%) was observed without differences 185 
within pediatric age groups (table 7). 186 
No significant differences among pediatric subgroups were observed in the rates of 187 
temporary interruption or in the rate of ADRs (25-38%). In addition, a high 188 
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compliance (greater than 70%) was observed in all groups and notably > 90%) in 189 
patients under 2 years old (Table 7).  190 
The most frequently observed pediatric ADRs were nutritional, followed by CNS 191 
adverse reactions, without clear differences among age groups. Headache was 192 
most frequent in children older than 7 years of age. Digestive and hematological 193 
events were mainly observed in children younger than 2 years old (Table 8).  194 
Discussion 195 
We present a large retrospective study of ChD patients (children and adults), 196 
treated with NF. We observed a low loss to follow-up, similar to other prospective 197 
pediatric and adult ChD studies (7, 8, 10, 11). Our service followed the standard of 198 
care guidelines for CD patients. However, as with any retrospective study 199 
conducted over a long period of time, possible sources of bias must be considered, 200 
due to insufficient detailed information about the incidence or severity of ADRs 201 
ADRs incidence in our study was strongly associated with patient age, since adults 202 
had higher incidence of ADRs and related treatment discontinuations than children. 203 
Moreover, NF-related ADRs were significantly more frequent in adults. Although 204 
pediatric pharmacologic studies on NF are still lacking, it is possible that observed 205 
differences in incidence of ADRs among the pediatric and adult sub-populations 206 
could be due to age-related differences in drug metabolism. NF is metabolized in 207 
the liver, and, similar to  many other drugs (12–14), it would be expected to 208 
undergo faster liver clearance in children compared to adults, leading in shorter 209 
half-lives and steady-state plasma concentrations. Pharmacological NF studies are 210 
currently underway to clarify this issue (www.clinicaltrials.gov  NCT01927224, 211 
NCT02625974). 212 
NF related ADRs had a lower incidence in our study compared to previous reports 213 
in children (6, 8, 10) and in adults (4, 6, 11)  Moreover, the rate of ADRs per patient 214 
in our adult cohort was 4-fold lower than the reported in previous studies (11). 215 
These differences could be explained by a larger sample size of our cohort that 216 
would yield a more accurate estimate of the incidence of ADRs and a shorter time 217 
of treatment (30 days) prescribed in our patients. However, some alternative 218 
explanations are possible, such as socio-economic, ethnical differences among the 219 
studied populations, detection bias (our data were retrospectively collected for this 220 
analysis), or other yet unknown issues.  221 
A high incidence of ADRs in patients with acute oral acute T.cruzi infection was 222 
reported (6). In our study we did not observe a higher incidence of ADRs in 223 
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patients during the acute phase of infection. This difference could be related to the 224 
different route of infection, mainly congenital, and that the majority of our cases 225 
were asymptomatic or with mild symptoms of infection  226 
Regarding severity, the ADRs observed in our cohort were mostly mild. Severe 227 
events were infrequent. and all patients recovered with no sequelae. This is 228 
comparable to previous studies in children (8, 10). However, in adult patients, we 229 
report a lower incidence of severe and serious adverse events than previous 230 
studies(4, 11).  231 
ADRs appeared earlier in adults than in children but most of them occurred within 232 
the first month of treatment, suggesting that most NF ADRs are not dependent on 233 
cumulative doses.   234 
ADRs profiles were similar between pediatric and adult populations, except for 235 
hematological ADRs, which appeared only in children, mainly those under 2 years 236 
of age. The most frequent ADRs were nutritional, mainly hyporexia and  weight 237 
loss, in line with the observations of many other ChD researchers (4, 7, 8, 11)  238 
CNS ADRs are a major concern. Seizures and psychiatric ADRs related to NF 239 
have been previously described (15). NF has a high level of fat solubility and is well 240 
distributed throughout the tissues, including the CNS. Even though NF is a 241 
substrate of breast cancer resistance protein (BCRP), which may be responsible 242 
for the active transfer of NF out of the CNS, it is possible that some patients may 243 
have BCRP polymorphisms that decrease this transfer, thus exposing them to high 244 
level of NF in the CNS for longer periods of time (i.e. exposing them to CNS ADRs) 245 
(16, 17).  However, this remains a hypothesis to be tested. We observed  mostly 246 
headaches and CNS irritability as NF ADRs (16). An adult patient presented 247 
tremors, dysarthria and panic attacks which required hospitalization, but recovered 248 
without consequences after temporary treatment interruption. Evaluation of CNS 249 
ADRs such as headaches, was difficult in children and particularly in infants 250 
because only older children can accurately express these symptoms. However, 251 
associated signs, such as unexplained irritability, food refusal, or vomiting, were 252 
not reported by caregivers or observed by our pediatricians who have significant 253 
experience in evaluating ChD pediatric patients. 254 
The profile of digestive ADRs was similar to that reported in other NF studies (4, 5, 255 
10, 11, 18). In children, digestive ADRs could be related to the lack of an 256 
appropriate pediatric formulation of NF which requires pill fractioning. As pill 257 
fragments are not easily (or willingly) swallowed by small children, this sometimes 258 
results in vomiting and other problems that may not be specifically related to the 259 
active drug. A new pediatric NF formulation in the late stages of clinical 260 
development (clinicaltrials.gov NCT02625974), over time, would eventually be 261 
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helpful to address the pediatric formulation gap and possibly decrease the 262 
incidence of digestive ADRs.  263 
Skin reactions are the main ADRs observed during treatment with the alternative 264 
drug BZ (19), but are much less frequently described with NF.  Accordingly, we 265 
observed few skin manifestations in our cohort, and only 3 children developed skin 266 
reactions that led to treatment discontinuation. The differences in ADR profiles 267 
between BZ and NF are not clearly explained to date, particularly given that they 268 
are both nitro-drugs. Unfortunately, NF metabolism, and metabolite profiles for both 269 
drugs remain poorly studied, which hampers any speculation on the 270 
pharmacological reasons behind these ADR differences (20, 21). 271 
Pediatric treatment discontinuation rates due to NF ADRs in our study were 272 
comparable with those in other studies (8, 10). Even though we observed higher 273 
discontinuation rates in adults compared to children, these adult rates (i.e. 14.3%) 274 
were lower than those reported in previous studies, which ranged from 19.8% to 275 
43.8% (4, 11). This difference could be due to the fact that most of the adult 276 
patients in our study were relatives of previously treated and cured children, to 277 
whom we offered treatment as part of our ChD family screening and treatment 278 
protocol. This population is highly motivated to persist and complete treatment.  279 
In summary, our results suggest that NF is a safe drug to use in both pediatric and 280 
adult ChD patients. Considering the retrospective nature of the study, these results 281 
are not conclusive and further prospective studies would be required in order to 282 
confirm our results. 283 
Since more primary infections of ChD occur during childhood, early diagnosis and 284 
treatment of children is vital to prevent long-term ChD sequelae. In the light of our 285 
findings, which strongly suggest, that NF is safe in childhood, we believe that 286 
treatment should not be delayed. 287 
 288 
Methods 289 
Study design and population 290 
This is a retrospective age-stratified study to assess safety and tolerability of oral 291 
NF in subjects with ChD.S All patients were treated and followed-up at the 292 
Parasitology and Chagas service, Hospital de Niños “Ricardo Gutiérrez”, Buenos 293 
Aires, Argentina from January 1980 to July 2019. 294 
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Patients were stratified according to age. Sub-analysis among children was done 295 
considering the following age groups: (0 - 7mos), (8mos - 1yr), (2 - 6yrs), (7- 296 
11yrs), (12 - 17yrs). 297 
Chagas Disease diagnostic criteria: For infants younger than 8 months: direct 298 
observation of T.cruzi using parasitological concentration method (microhematocrit 299 
test, MH) or xenodiagnosis (XD); for older patients: 2 reactive serological tests: 300 
Enzyme Linked Immunosorbent Assay (ELISA), Indirect Hemagglutination (IHA) or 301 
Direct  agglutination (DA).  302 
Exclusion criteria: Cases where nifurtimox was prescribed but not taken (patients 303 
did not come back; n = 52) or cases where medication data was not properly 304 
documented. (n = 10). 305 
Study population: For the safety analysis, all patients who started treatment were 306 
considered, regardless of whether or not they completed the treatment.  307 
 308 
Treatment 309 
NF treatment (120-mg tablets, Bayer) was prescribed in doses of 10-15 mg per kg 310 
per day divided in two or three daily doses for 60 to 90 days for infants and 311 
children, and 8-10 mg per kg for 30 days for adults, according to national 312 
guidelines at the moment of diagnosis. Note that regimens were modified for 313 
shorter treatment in the last years. Enrollment of children started in January 1980, 314 
and enrollment of adults started in July 2008. Infant NF doses were provided as 315 
fractionated tablets prepared by a pharmacist and administered with water or 316 
mother's milk. Medication was provided to patients or their guardians in monthly 317 
batches, and compliance was assessed by counting remaining tablets at each visit.  318 
Treatment was considered complete when patients took the medication for at least 319 
60 days for children and 30 days for adults. 320 
Data Collection 321 
Data were collected from medical records of treated patients and entered into an 322 
Access clinical database (ACD) designed for this study. All individual datasets 323 
were anonymized.  324 
Demographic data, clinical and biochemical assessments and complementary 325 
studies were collected during follow-up. Baseline data values were obtained at the 326 
beginning of the treatment. Following the standard of care of our service for CD 327 
treated patients, visits were carried out at 7, 30 days and at the end of treatment, 328 
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every 3 months during the first-year post-treatment and every 6 -12 months 329 
thereafter.  330 
 331 
ADRs were evaluated through laboratory tests, clinical interviews and physical 332 
examinations, and classified according to World Health Organization (WHO) 333 
definitions (22, 23). Causality assessment was performed using the WHO criteria 334 
for causality assessment   335 
Information on treatment duration and dosage, temporary interruptions and 336 
concomitant medications was systematically collected from medical records and 337 
documented in the clinical Database.  338 
Statistical Analysis 339 
Continuous variables were expressed with mean and median, as applicable, with 340 
the corresponding standard deviation or interquartile range. Categorical variables 341 
were expressed in percentages. To test for significance, as appropriate, T test or 342 
Wilcoxon unpaired rank test (W.T.) for continuous variables and Fisher exact tests 343 
(F.E.T.) for categorical ones. P-values were adjusted by false discovery rate 344 
(Benjamini-Hochberg procedure). Adjusted p-values with PAdjusted < 0.05 were 345 
considered statistically significant. The statistical package R was used (24).  346 
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Fig. 1. Study flowchart. Medical records included in this study are described in the figure. 358 
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TABLES     359 
Table 1. Demographic data.   360 
 Children (%) Adults (%) Total Patients (%) 
Gender    
F 109 (50.7) 92 (87.6) 201 (62.8) 
M 106 (49.3) 13 (12.4) 119 (37.2) 
Age (months)    
Median [Q1, Q3] 31.0 [6.00, 108] mos. 34 [29, 38] yrs. - 
Mean (SD) 59.5 (63.1) mos. 34.5 (7.37) yrs. - 
Min-Max 1.00-215 mos. 19-57 yrs. - 
Route of Infection    
Vector 22 (10.2) 10 (9.5) 32 (10.0) 
Congenital 120 (55.8) 11 (10.5%) 131 (40.9) 
Blood transfusion 1 (0.5) 2 (1.9) 3 (0.9) 
Undetermined 72 (33.5) 82 (78.1) 154 (48.1) 
Clinical Examination 
at diagnosis    
Asymptomatic 185(86.0) 104(99.0) 289(90.3) 
Symptomatic 30(14.0) 1(1.0) 31(9.7) 
Total 215(67) 105(33) 320(100) 
F: Female, M: Male  361 
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Table 2. Adverse events classified by severity and their relationship to treatment 362 
 Children Adults 
 
Patients (%) 
n = 63 
Number of 
ADRs (%)  
n = 84 
Patients (%) 
n = 64 
Number of 
ADRs (%) 
n = 131 
Severity     
Mild 47 (74.6) 60 (71.4) 54 (84.4) 101 (77.1) 
Moderate 8 (12.7) 8 (9.5) 14 (21.9) 27 (20.6) 
Severe 1 (1.6) 1 (1.2) 1 (1.6) 1 (0.8) 
No-Data 11 (17.5) 15 (17.9) 1 (1.6) 2 (1.5) 
Relationship     
Not Related 5 (7.9) 10 (11.9) 2 (3.1) 2 (1.5) 
Unlikely 1 (1.6) 1 (1.2) 1 (1.6) 1 (0.8) 
Probable 47 (74.6) 53 (63.1) 20 (31.2) 31 (23.7) 
Certain 5 (7.9) 5 (6) 51 (79.7) 95 (72.5) 
No-Data 11 (17.5) 15 (17.9) 1 (1.6) 2 (1.5) 
Total 63 (100.0) 84 (100.0) 64 (100.0) 131 (100.0) 
Relationship classification was recorded according to OMS criteria. For each age group, two columns are 363 
shown. The first one, Patients with ADRs, shows the number of patients presenting at least one ADR and its 364 
corresponding percentage. The second column, Number of ADRs, depicted the observed number of ADRs and 365 
its corresponding percentage. Notice that patients could present more than one ADR belong to different 366 
categories (i.e Mild - Moderate).   367 
  368 
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Table 3.  ADR occurrence and patient incidence by organ system.  370 
 Children Adults 
 
Patients (%) 
n = 63 
Number of 
ADRs (%) 
n = 84 
Patients (%) 
n = 64 
Number of ADRs 
(%)  
n = 131 
Body as a whole 1 (1.6) 1 (1.2) 4 (6.2) 4 (3.1) 
Fever 1 (1.6) 1 (1.2) 2 (3.1) 2 (1.5) 
Asthenia - - 2 (3.1) 2 (1.5) 
Cardiovascular - - 2 (3.1) 2 (1.5) 
Syncope - - 1 (1.6) 1 (0.8) 
Tachycardia - - 1 (1.6) 1 (0.8) 
Digestive 11 (17.5) 12 (14.3) 21 (32.8) 26 (19.8) 
Vomiting 8 (12.7) 8 (9.5) 4 (6.2) 4 (3.1) 
Nausea 2 (3.2) 2 (2.4) 8 (12.5) 8 (6.1) 
Dyspepsia 1 (1.6) 1 (1.2) 8 (12.5) 8 (6.1) 
Abdominal pain 1 (1.6) 1 (1.2) 4 (6.2) 4 (3.1) 
Others - - 2 (3.1) 2 (1.5) 
Hematological 6 (9.5) 7 (8.3) - - 
Eosinophilia 3 (4.8) 3 (3.6) - - 
Leukopenia 3 (4.8) 3 (3.6) - - 
Plaquetopenia 1 (1.6) 1 (1.2) - - 
Nutritional 30 (47.6) 31 (36.9) 40 (62.5) 44 (33.6) 
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Weight loss 13 (20.6) 13 (15.5) 33 (51.6) 33 (25.2) 
Hyporexia 18 (28.6) 18 (21.4) 11 (17.2) 11 (8.4) 
Musculoskeletal 1 (1.6) 1 (1.2) 2 (3.1) 2 (1.5) 
Myalgias - - 2 (3.1) 2 (1.5) 
Chest pain 1 (1.6) 1 (1.2) - - 
CNS 19 (30.2) 22 (26.2) 28 (43.8) 39 (29.8) 
Headache 6 (9.5) 6 (7.1) 20 (31.2) 20 (15.3) 
Irritability 15 (23.8) 15 (17.9) 7 (10.9) 7 (5.3) 
Dizziness - - 5 (7.8) 5 (3.8) 
Others 1 (1.6) 1 (1.2) 5 (7.8) 7 (5.3) 
Respiratory 1 (1.6) 3 (3.6) - - 
Acute bronchitis 1 (1.6) 1 (1.2) - - 
Rhinorrhea 1 (1.6) 1 (1.2) - - 
Influenza Syndrome 1 (1.6) 1 (1.2) - - 
Skin 6 (9.5) 7 (8.3) 10 (15.6) 13 (9.9) 
Rash 6 (9.5) 7 (8.3) 6 (9.4) 6 (4.6) 
Urticaria - - 4 (6.2) 4 (3.1) 
Others - - 3 (4.7) 3 (2.3) 
Psychiatric - - 1 (1.6) 1 (0.8) 
Depression - - 1 (1.6) 1 (0.8) 





























Detailed description of the 215 ADRs occurring in the 127 patients segregated by organ system. 372 
For each age group, two columns are shown. The first column, Patients with ADRs, shows the 373 
number of patients presenting at least one ADR and its corresponding percentage. The second 374 
column, Number of ADRs, depicted the observed number of ADRs and its corresponding 375 
percentage.  Low frequency symptoms were grouped into a general category, namely, “others”. 376 
digestive: (epigastralgia; pyrrhosis). CNS:(depression; nightmare; dysarthria; insomnia; loss of 377 
memory; panic attacks; tinnitus). Skin: (facial edema; pruritus).  378 
  379 
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Table 4. Treatment discontinuation and interruption.  381 
 Children (%) Adults (%) Total Patients (%) 
Complete treatment    
Yes 199 (92.6) 90 (85.7) 289 (90.3) 
No 16 (7.4) 15 (14.3) 31 (9.7) 
Discontinuation cause    
Patient Decision 6 (2.8) 1 (1.0) 7 (2.2) 
Adverse Effect 4 (1.9) 10 (9.5) 14 (4.4) 
Death 1 (0.5) - 1 (0.3) 
Lost of follow-up 5 (2.3) 4 (3.8) 9 (2.8) 
Treatment Complete 199 (92.6) 90 (85.7) 289 (90.3) 
Temporary Interruption    
Yes 10 (4.7) 10 (9.5%) 20 (6.2) 
No 205 (95.3) 95 (90.5) 300 (93.8) 
Total 215 (67.0) 105 (33.0) 320(100.0) 
Detailed description of reasons of treatment discontinuation and interruption for all patients included 382 
in this study (n = 320 patients).      383 
  384 
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Gender Symptoms Treatment 
Length (days) 
Second Treatment 
Pediatrics 0-1 F Irritability 15 NF, Completed 
 7-17 M Rash 15 - 
 7-17 F Rash 27 - 




Adults 30-39 F Headache, Irritability, 
Nausea 
3 BZ, discontinued 
because of ADR 
 40-49 F Hiporexia 23 BZ, Completed 
 50-59 F Hiporexia 11 BZ, Completed 
 30-39 F Syncope, Dizziness, 
Headache, 
Dyspepsia, Nausea 
12 BZ, Completed 
 40-49 F Headache, Abdominal 
pain 
15 - 
 20-29 F Abdominal pain, 
Vomiting, Myalgias 
11 - 
 30-39 F weight loss, Irritability, 
tremors, dysarthria, 
Panic attack 
18 BZ, discontinued 
because of ADR 
 20-29 F Rash, Itching, 
Headache, Dyspepsia 
12 BZ, Completed 
 30-39 F Headache. Dizziness 8 BZ, Completed 
 30-39 F Psychomotor agitation 10 BZ, discontinued 
because of ADR 
Detailed ADR description for those patients who discontinued treatment due to ADRs. NF: nifurtimox, BZ: 386 
benznidazole. All patients had a good response to symptomatic treatment.    387 
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Table 6: Treatment description.  388 
 Children Adults Total Patients 
Dose (mg/kg body 
weight)    
Median [Q1, Q3] 11.0 [10.0, 12.0] 9.00 [8.20, 9.70] 10.0 [9.19, 12.0] 
Missing (%) 5 (2.5) - 5 (1.7) 
Number of doses    
Median [Q1, Q3] 2.00 [2.00, 3.00] 2.00 [2.00, 3.00] 2.00 [2.00, 3.00] 
Missing (%) 6 (3.0) - 6 (2.1) 
Days of treatment    
Median [Q1, Q3] 62.0 [60.5, 73.0] 30.0 [29.0, 32.0] 61.0 [33.0, 69.0] 
Concomitant 
medication 
   
Yes (%) 3 (1.5) - 3 (1.0) 
No (%) 196 (98.5) 90 (100) 286 (99.0) 
Compliance    
Yes (%) 166 (83.4) 75 (83.3) 241 (83.4) 
No (%) 33 (16.6) 15 (16.7) 48 (16.6) 
Temporary 
Interruption 
   
Yes (%) 7 (3.5) 8 (8.9) 15 (5.2) 
No (%) 192 (96.5) 82 (91.1) 274 (94.8) 
Total 199 (92.6) 90 (100) 289 (90.3) 
Treatment dosification, length and concomitant medication for all patients that completed NF treatment 389 
(n=289).    390 
 on N
ovem


























Table 7:  Treatment details for the pediatric cohort.          392 
 (0-7mos) 
Patients (%)  
n = 56 
(8mos - 1yr)  
Patients (%) 
n = 43 
 
(2 - 6yrs) 
Patients (%) 
n = 44 
 
(7 - 11yrs) 
Patients (%) 
n = 37 
 
(12 - 17yrs) 
Patients (%) 
n = 35 
Total 
Patients (%) 
n = 215 
Complete 
Treatment 
      
Yes 53 (94.6) 41 (95.3) 41 (93.2) 35 (94.6) 29 (82.9) 199 (92.6) 
No 3 (5.4) 2 (4.7) 3 (6.8) 2 (5.4) 6 (17.1) 16 (7.4) 
Treatment 
discontinuation 
      
Patient 
decision 
- 1 (2.3) 2 (4.5) 1 (2.7) 2 (5.7) 6 (2.8) 
Adverse event - 1 (2.3) 1 (2.3) 0 (0) 2 (5.7) 4 (1.9) 
Death 1 (1.8) - - - - 1 (0.5) 
Loss of follow-
up 
2 (3.6) - - 1 (2.7) 2 (5.7) 5 (2.3) 
Temporary 
Interruption 
      
Yes 2 (3.6) 1 (2.3) 2 (4.5) 1 (2.7) 4 (11.4) 10 (4.7) 
No 54 (96.4) 42 (97.7) 42 (95.5) 36 (97.3) 31 (88.6) 205 (95.3) 
Compliance       
Yes 48 (90.6) 37 (90.2) 29 (70.7) 27 (73.0) 25 (71.4) 166 (83.4) 
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No 5 (9.4) 4 (9.8 12 (29.3) 12 (27.0) 10(28.6) 33 (16.6) 
Adverse Events       
Yes 14 (25.0) 14 (32.6) 17 (38.6) 11 (29.7) 7 (20.0) 63 (29.3) 




      
Median [Q1, 
Q3] 
1.0 [1.0, 1.00] 1.0 [1.0, 1.0] 1.0 [1.0, 2.0] 1.0 [1.00, 1.0] 2.0 [1.0, 2.0] 1.0 [1.0, 1.5] 
       
Treatment completion, compliance, interruption and discontinuation causes for different age groups 393 
in the pediatric cohort. Also, the number and rates of adverse events are shown394 
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Table 8: ADR occurrence and patient incidence by organ system in the pediatric cohort.  396 
 




n = 14 
Number of 
ADRs (%) 




n = 14  
Number of 
ADRs (%) 











n = 11 
Number of 
ADRs (%) 




n = 7 
Number of 
ADRs (%) 
n = 14 
Body as a whole - - - - 1 (5.9) 1 (4.2) - - - - 
Fever - - - - 1 (5.9) 1 (4.2) - - - - 
Digestive 4 (28.6) 4 (23.5) 2 (14.3) 2 (12.5) 2 (11.8) 2 (8.3) - - 3 (42.9) 4(28.6) 
Vomiting 4 (28.6) 4 (23.5) 2 (14.3) 2 (12.5) 1 (5.9) 1 (4.2) - - 1 (14.3) 1(7.1) 
Nausea - - - - - - - - 2 (28.6) 2(14.3) 
Dyspepsia - - - - - - - - 1 (14.3) 1(7.1) 
Abdominal pain - - - - 1 (5.9) 1 (4.2) - - - - 
Hematological 2 (14.3) 2 (11.8) 2 (14.3) 3 (18.7) 1 (5.9) 1 (4.2) 1 (9.1) 1(7.7) - - 
Eosinophilia - - 1 (7.1) 1 (6.2) 1 (5.9) 1 (4.2) 1 (9.1) 1(7.7) - - 
Leukopenia 2 (14.3) 2(11.8) 1 (7.1) 1 (6.2) - - - - - - 
Plaquetopenia - - 1 (7.1) 1 (6.2) - - - - - - 
Nutritional 6 (42.9) 6 (35.3) 8 (57.1) 8 (50) 8 (47.1) 8 (33.3) 5 (45.5) 5(38.5) 3 (42.9) 4(28.6) 
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Weight loss 1 (7.1) 1 (5.9) 4 (28.6) 4 (25) 3 (17.6) 3 (12.5) 3 (27.3) 3(23.1) 2 (28.6) 2(14.3) 
Hiporexia 5 (35.7) 5 (29.4) 4 (28.6) 4 (25) 5 (29.4) 5 (20.8) 2 (18.2) 2(15.4) 2 (28.6) 2(14.3) 
Musculoskeletal - - - - - - 1 (14.3) 1(7.1) - - 
Chest pain - - - - - - 1 (14.3) 1(7.1) - - 
CNS 3 (21.4) 3 (17.6) 3 (21.4) 3 (18.7) 8 (47.1) 10 (41.7) 5 (45.5) 6(46.2) - - 
Headache - - - - 2 (11.8) 2 (8.3) 4 (36.4) 4(30.8) - - 
Irritability 3 (21.4) 3 (17.6) 3 (21.4) 3 (18.7) 7 (41.2) 7 (29.2)  2 (18.2) 2(15.4) - - 
   Nightmare - - - - 1 (5.9) 1 (4.2) - - - - 
Respiratory - - - - - - 1 (14.3) 3(21.4) - - 
Acute bronchitis - - - - - - 1 (5.6) 1 (3.7) - - 
Rhinorrhea - - - - - - 1 (5.6) 1 (3.7) - - 
Influenza 
Syndrome 
- - - - - - 
1 (14.3) 1(7.1) 
- - 
Skin 2 (14.3) 2 (11.8) - - 2 (11.8) 2 (8.3) 1 (9.1) 1(7.7) 1 (14.3) 2(14.3) 
Rash 2 (14.3) 2 (11.8) - - 2 (11.8) 2 (8.3) 1 (9.1) 1(7.7) 1 (14.3) 2(14.3) 
Total  14(100) 17 (100) 14(100) 16(100) 17(100) 24(100) 11(100) 13 (100) 7 (100) 14 (100) 
 397 
Detailed description of the 84 ADRs occurring in the 64 pediatric patients segregated by organ 398 
system. For each age group, the first column, Patients with ADRs, displays the number of patients 399 
presenting at least one ADR and its corresponding percentage. The second column, Number of 400 
ADRs, depicted the observed number of ADRs and its corresponding percentage.401 
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